FDA Resolves Tirzepatide Shortage, New Drugs Available

The FDA has lifted the shortage status of tirzepatide, a dual agonist approved for type 2 diabetes and obesity, confirming Eli Lilly's capacity to meet demand. Research indicates that tirzepatide and semaglutide lead to greater weight loss compared to other obesity medications without increasing adverse event risks. Meanwhile, studies show that semaglutide may reduce motivation to exercise, potentially dampening the rewarding aspects of physical activity. The rising demand for GLP-1 medications like Ozempic and Wegovy has sparked an illegal black market, as seen in a CNBC investigation revealing counterfeit drugs being sold online. In response to misuse, France's Medicines Safety Agency has implemented new restrictions on prescribing GLP-1 drugs, limiting initiation to specialists and ensuring proper treatment protocols. WeightWatchers has also entered the market by offering compounded versions of Wegovy, reflecting the growing integration of obesity medications into weight management programs.